Web Analytics

3 Latest Announced Rounds

$1,325.73M Raised in 74 Funding Rounds in the past 7 Days - View All

Funding Round Profile

Shinobi Therapeutics

start up
United States - South San Francisco, CA
  • 13/12/2023
  • Series A
  • $51,000,000

Shinobi Therapeutics is developing a new class of hypoimmune CD8ab iPS-T cells for cancer and beyond by using immune evasion to unlock the full potential of iPSCs.


Related People

Dan KempFounder

Dan Kemp United States - New York City Metropolitan Area

Accomplished BioPharma Executive with experience in drug discovery (Novartis), translational and clinical development (Merck), sell-side, buy-side and M&A transactional BD (Takeda), Executive oversight (GammaDelta Therapeutics, Adaptate Therapeutics) and Operational Leadership (Cell Therapies at Takeda).